Chronic Graft Versus Host Disease
Specialty Channel

Featured Article
True or False: According to study findings, belumosudil, an oral ROCK2 inhibitor, has shown promising efficacy in the treatment of patients with cGVHD.
Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.
________ yields tolerability for the prevention of acute graft-versus-host disease by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the…
True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
True or False: This year, Ruxolitinib, a selective Janus kinase inhibitor, showed potential efficacy for glucocorticoid-refractory acute GVHD in a phase 2 trial.
True or False: Itpkb signaling is essential to drive acute GVHD pathogenesis and sustain active chronic GVHD.
In a phase 2 clinical trial, which prophylaxis regimens yielded the best GVHD-free relapse-free survival in adults who underwent reduced-intensity conditioning allogeneic hematopoietic cell…

News

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with cGVHD.
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

Interactive Features

True or False: According to study findings, belumosudil, an oral ROCK2 inhibitor, has shown promising efficacy in the treatment of patients with cGVHD.
________ yields tolerability for the prevention of acute graft-versus-host disease by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the…
True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
Stay in the know.
OncNet Newsletter